BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tasneem M, Mannix C, Wong A, Zhang J, Rangan G. Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease? World J Nephrol 2018; 7(2): 51-57 [PMID: 29527508 DOI: 10.5527/wjn.v7.i2.51]
URL: https://www.wjgnet.com/2220-6124/full/v7/i2/51.htm
Number Citing Articles
1
Stéphanie De Rechter, Bert Bammens, Franz Schaefer, Max C Liebau, Djalila Mekahli. Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspectiveClinical Kidney Journal 2018; 11(suppl_1): i14 doi: 10.1093/ckj/sfy088
2
Alessandro Maria Berton, Emanuele Varaldo, Nunzia Prencipe, Francesca Rumbolo, Fabio Settanni, Andrea Benso, Silvia Grottoli. Attuali applicazioni della determinazione dei livelli plasmatici di copeptina in contesti non-endocrinologiciL'Endocrinologo 2022; 23(6): 592 doi: 10.1007/s40619-022-01180-8
3
Kuldeep Dhama, Shyma K. Latheef, Maryam Dadar, Hari Abdul Samad, Ashok Munjal, Rekha Khandia, Kumaragurubaran Karthik, Ruchi Tiwari, Mohd. Iqbal Yatoo, Prakash Bhatt, Sandip Chakraborty, Karam Pal Singh, Hafiz M. N. Iqbal, Wanpen Chaicumpa, Sunil Kumar Joshi. Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic ValuesFrontiers in Molecular Biosciences 2019; 6 doi: 10.3389/fmolb.2019.00091
4
Thomas Roe, Jessie Welbourne, Nikitas Nikitas. Endocrine dysregulation in aneurysmal subarachnoid haemorrhageBritish Journal of Neurosurgery 2022; 36(3): 358 doi: 10.1080/02688697.2022.2039378